Anti-beta Tubulin antibody
| Name | Anti-beta Tubulin antibody |
|---|---|
| Supplier | Abcam |
| Catalog | ab21057 |
| Prices | $391.00 |
| Sizes | 100 µg |
| Host | Goat |
| Clonality | Polyclonal |
| Isotype | IgG |
| Applications | WB ICC/IF ICC/IF |
| Species Reactivities | Mouse, Human, Monkey, Rat, Chicken |
| Antigen | Synthetic peptide derived from within residues 1 - 100 of Human beta Tubulin |
| Description | Goat Polyclonal |
| Gene | TUBB |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
All lanes : Anti-beta Tubulin antibody (ab21057) at 1 µg/mlLane 1 : HeLa whole cell lysateLane 2 : HeLa whole cell lysate with Human beta Tubulin peptide (ab20775) at 1 µg/mlLysates/proteins at 20 µg per lane.SecondaryRabbit anti Goat polyclonal at 1/10000 dilution
Ab21057 staining beta-tubulin in asynchronous HeLa cells (green). Cells were counterstained with DAPI (red) to show the nucleus. Secondary antibody: Donkey anti-Goat antibody conjugated to Alexafluor 488 ® (Please refer to the Abreview for further details).See Abreview
developed using the ECL techniquePerformed under reducing conditions.
Product References
Soluble CEACAM8 interacts with CEACAM1 inhibiting TLR2-triggered immune - Soluble CEACAM8 interacts with CEACAM1 inhibiting TLR2-triggered immune
Singer BB, Opp L, Heinrich A, Schreiber F, Binding-Liermann R, Berrocal-Almanza LC, Heyl KA, Muller MM, Weimann A, Zweigner J, Slevogt H. PLoS One. 2014 Apr 17;9(4):e94106.
Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic - Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic
Gammons MV, Lucas R, Dean R, Coupland SE, Oltean S, Bates DO. Br J Cancer. 2014 Jul 29;111(3):477-85.
Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in - Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in
Gammons MV, Fedorov O, Ivison D, Du C, Clark T, Hopkins C, Hagiwara M, Dick AD, Cox R, Harper SJ, Hancox JC, Knapp S, Bates DO. Invest Ophthalmol Vis Sci. 2013 Sep 5;54(9):6052-62.
Ovarian cancer progression is controlled by phenotypic changes in dendritic - Ovarian cancer progression is controlled by phenotypic changes in dendritic
Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, Cubillos-Ruiz JR, Jacobs AC, Gonzalez JL, Weaver J, Fiering S, Conejo-Garcia JR. J Exp Med. 2012 Mar 12;209(3):495-506.
Global analysis of genome, transcriptome and proteome reveals the response to - Global analysis of genome, transcriptome and proteome reveals the response to
Stingele S, Stoehr G, Peplowska K, Cox J, Mann M, Storchova Z. Mol Syst Biol. 2012;8:608.
Studies of haspin-depleted cells reveal that spindle-pole integrity in mitosis - Studies of haspin-depleted cells reveal that spindle-pole integrity in mitosis
Dai J, Kateneva AV, Higgins JM. J Cell Sci. 2009 Nov 15;122(Pt 22):4168-76.